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Abstract
Aims/hypothesis Energy-dense diets that are high in fat are
associated with a risk of metabolic diseases. The underlying
molecular mechanisms could involve epigenetics, as recent
data show altered DNA methylation of putative type 2
diabetes candidate genes in response to high-fat diets. We
examined the effect of a short-term high-fat overfeeding
(HFO) diet on genome-wide DNA methylation patterns in
human skeletal muscle.
Methods Skeletal muscle biopsies were obtained from 21
healthy young men after ingestion of a short-term HFO diet
and a control diet, in a randomised crossover setting. DNA
methylation was measured in 27,578 CpG sites/14,475 genes
using Illumina's Infinium Bead Array. Candidate gene expres-
sion was determined by quantitative real-time PCR.
Results HFO introduced widespread DNA methylation
changes affecting 6,508 genes (45%), with a maximum methyl-
ation change of 13.0 percentage points. The HFO-induced
methylation changes were only partly and non-significantly
reversed after 6–8weeks. Alterations inDNAmethylation levels
primarily affected genes involved in inflammation, the repro-
ductive system and cancer. Few gene expression changes were
observed and these had poor correlation to DNA methylation.
Conclusions/interpretation The genome-wide DNAmethyla-
tion changes induced by the short-term HFO diet could have
implications for our understanding of transient epigenetic reg-
ulation in humans and its contribution to the development of
metabolic diseases. The slow reversibility suggests a methyla-
tion build-up with HFO, which over time may influence gene
expression levels.
Keywords DNAmethylation . Epigenetic .Geneexpression .
Genome-wide . High-fat overfeeding . Human . Illumina
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Abbreviations
HFO High-fat overfeeding
IR Insulin resistance
SOM Self-organising map
Introduction
DNA methylation at CpG sites is an important and potentially
heritable epigenetic modification of the mammalian genome
[1]. DNA methylation can affect gene expression and
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chromosome stability, potentially influencing phenotypic out-
comes in health and disease [2, 3]. Examples of such modifi-
cations are known from some types of cancer, where
hypomethylation of oncogenes and hypermethylation of tu-
mour suppressor genes are supposed components in cancer
development [2, 4, 5]. Epigenetic profiles are influenced by
genetics [6–8], but ageing and environmental factors including
diet, chemicals and smoking may take centre-stage in the
control of DNA methylation [9–12]. Studies have indicated
that DNA methylation may play a role in metabolic diseases
such as diabetes. Differential methylation has been identified
in the promoter region of the key metabolic regulator peroxi-
some proliferator-activated receptor gamma coactivator 1 al-
pha (PPARGC1A) gene and in 1.8% of 14,475 genes examined
in recent methylation profiling in pancreatic islets from type 2
diabetic patients [13, 14]. Furthermore, increased methylation
of PPARGC1A has been found in the skeletal muscle of
patients with glucose intolerance and type 2 diabetes [15], as
well as in muscle from low-birthweight individuals with an
increased risk of type 2 diabetes [16].
Diet is a highly influential factor in the origin of meta-
bolic disease, and both specific dietary components as well
as shifts in overall dietary regimens can affect DNA meth-
ylation levels. It is well established that diets rich in genis-
tein [17] and methyl donors [12] are able to modulate DNA
methylation patterns in the rodent offspring of mothers
consuming such diets, influencing the offspring's incidence
of obesity, diabetes and cancer in a potentially transgenera-
tional manner [1, 12, 17]. Diets high in fat have been shown
to increase DNA methylation of the leptin promoter [18] and
to prolong the presence of general DNA methylation in-
duced by treatment with carcinogenic agents in rats [19,
20]. Limited data are available in humans. However, we
recently found that a high-fat overfeeding (HFO) diet in-
creased DNA methylation of the PPARGC1A promoter in
the skeletal muscle of young healthy men in a reversible
manner [16]. This finding is supported by studies of human
muscle cells, where exposure to fatty acids in vitro likewise
increased methylation of PPARGC1A [15]. These data sug-
gest that DNA methylation changes could be associated
with the development of skeletal muscle insulin resistance
(IR) in type 2 diabetes and in people at risk of this disease
[15, 16]. Based on these recent findings, we hypothesised
that a short-term HFO diet may introduce additional and
potentially widespread DNA methylation changes in human
skeletal muscle, affecting genes belonging to distinct path-
ways influencing the risk of metabolic disease.
Methods
Participants A total of 26 men aged 24.6±1.1 (mean ± SD)
years were recruited according to a previous description
[21]. The participants were born at term with birthweights
in the 50–90th percentile. None of the participants had a
family history of diabetes, BMI above 30 kg/m2 or high
physical activity levels (>10 h/week). The protocol con-
formed to the Helsinki Declaration, and was approved by
the Ethics Committee for Copenhagen County and the Dan-
ish Data Protection Agency. All the participants gave in-
formed consent before study participation.
Dietary intervention In a randomised crossover setting, all
21 participants completed both the HFO intervention and
the control period separated by a washout period of 6–
8 weeks (Fig. 1). The study design has previously been
thoroughly described [21]. In brief, the participants were
standardised with respect to physical activity, alcohol con-
sumption and diet 5 days prior to both examinations and
were asked to remain weight stable between the examination
periods. The HFO diet was delivered to the participants for
5 days, starting 5 days prior to excursion of skeletal muscle
biopsies. The HFO intervention diet contained 50% extra
calories distributed as 60% fat, 32.5% carbohydrate and
7.5% protein. While the standardisation of the control peri-
od also included 5 days in total, compliance was optimised
even further during the last 3 out of the 5 days by providing
identical meals to all participants. The control diet contained
35% fat, 50% carbohydrate and 15% protein.
Clinical examinations Detailed clinical andmetabolic exami-
nations were performed in the participants and have been
previously published [21]. Blood samples were drawn in the
fasting state and throughout the examination period to mea-
sure, among others, glucose, insulin, NEFA, triacylglycerol
and cholesterol levels. TheM value was calculated as: glucose
infusion (μmol/min)/fat-free mass in kg. Hepatic IR index was
calculated as: endogenous (hepatic) glucose production
[(μmol/min)/fat-free mass in kg] × fasting serum insulin
(pmol/l). Biopsies were excised frommusculus vastus lateralis
Study population (n=26)
Control diet (n=11)
Control diet
Excluded (n=5)
• No muscle biopsy available
Washout period 6–8 weeks
HFO diet (n=10)
HFO diet
Fig. 1 Design overview. A total of 21 participants were randomised
into one of two dietary groups. The control diet first group (n011)
consumed a control diet followed by an HFO diet, while the HFO first
group (n010) received an HFO diet initially followed by a control diet.
The two dietary periods were separated by a washout period of 6–
8 weeks
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using a Bergström needle, immediately frozen in liquid nitro-
gen and stored at −80°C.
DNA methylation profiling: Illumina's 27k Bead Array Me-
thylation was assessed at 27,578 CpG sites associated with
14,475 genes using Illumina's 12-sample InfiniumBeadArray
Methylation Chip (Illumina, San Diego, CA, USA). Genomic
DNAwas extracted using the DNeasy kit (Qiagen, Valencia,
CA, USA). A total of 600 ng DNAwas bisulfite-treated with
the EZ DNA Methylation kit (Zymo Research, Orange, CA,
USA). Each sample was whole-genome amplified and enzy-
matically fragmented. The whole-genome amplified–DNA
samples were purified and hybridised to two different bead
spots, methylated-Cy5 or unmethylated-Cy3, followed
by single-base extension using DNP- and biotin-labelled
dideoxynucleoside triphosphates. The methylation status at
each CpG site was averaged over 30 replicate measurements
and determined by the ratio of the fluorescent signal from Cy5
relative to the combined intensity, and recorded as β values
between 0 and 1 corresponding to 0–100% methylation using
BeadStudio Methylation Module v.3.2 (Illumina).
Validation of results from the bead array Validation of
selected array results was performed using Sequenom's
MassARRAY EpiTYPER (Sequenom, San Diego, CA,
USA) or Qiagen's Pyrosequencing (Qiagen, Valencia, CA,
USA). Initially, 200–500 ng DNAwas bisulfite-treated with
the EZ Gold DNA Methylation kit (Zymo Research).
MassARRAY EpiTYPER PCR was performed with bisulfite-
specific primers (EpiDesigner; Sequenom). Transcription
and cleavage was completed using the MassCleave kit
(Sequenom, San Diego, CA, USA) and mass spectra ac-
quired using the MassARRAY mass spectrometer (Seque-
nom, San Diego, CA, USA). DNA methylation levels were
calculated by comparing mass signal intensity between
methylated and non-methylated template DNA. The spectra
were analysed using the EpiTYPER software v.1.0.1.
Pyrosequencing PCR was performed by the PyroMark PCR
kit (Qiagen, Valencia, CA, USA) with primers designed
using the PyroMark Assay Design Software 2.0. The sam-
ples were prepared using the PyroMark Q96 Vacuum Work-
station and sequenced on the PyroMark Q96 ID instrument
with bisulfite conversion controls. Data were analysed using
the Pyrogram software v.2.5.7.
Quantitative real-time PCR Gene expression was deter-
mined for 13 selected candidate genes of type 2 diabetes,
methyltransferase enzymes and biologically relevant genes
showing large or significant DNA methylation changes fol-
lowing HFO. Total RNA was extracted from the muscle
biopsies using TRI Reagent (Sigma-Aldrich, St Louis, MO,
USA). cDNA was synthesised using the QuantiTect Reverse
Transcription Kit (Qiagen). mRNA expression was detected
with the ABI 7900 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using gene-specific prim-
er/probe pairs for ACAT2 (Hs00255067_m1), ADAMTS9
(Hs00172025_m1), AKT2 (Hs01086102_m1), DNM2
(Hs00974698_m1), DNMT1 (Hs00154749_m1), DNMT3A
(Hs01027166_m1), DNMT3B (Hs00171876_m1), ESRRG
(Hs00155006_m1), LMNA (Hs00153462_m1), MGMT
(Hs01037698_m1), MRC1 (Hs00267207_m1), MYST4
(Hs00202463_m1) and PPARGC1A (Hs00173304_m1) (Ap-
plied Biosystems). All samples were run in duplicate and the
standard curve approach was used for quantification. The
transcript quantity was normalised to mRNA levels of PPIA
(4326316E, Applied Biosystems), which did not vary with
experimental conditions.
Statistical methods The bisulfite-treated DNA samples were
distributed on nine different 12-sample arrays with an even
division of control andHFO samples to eliminate any technical
effects. The raw β values were normalised with the BeadStu-
dio software, as recommended by Illumina. Illumina's internal
controls supported successful array preparation and poor sam-
ple performance was eliminated. According to the detection
p value (>0.05), 0.2% of the data points were eliminated
alongside three CpG sites with a mean detection p value
of >0.05. Statistical analyses were performed using the
programming language R version 2.9.0 (www.r-project.org).
Normality was evaluated by Kolmogorov–Smirnov's normal-
ity test and normality plots. Data were analysed with paramet-
ric tests, and data are presented as mean ± SD and differences
between two methylation percentages are given as percentage
points. p values ≤0.05 were considered statistical significant
and p values ≤0.10 in the validation analyses were defined as
borderline statistically significant. Benjamini–Hochberg's false
discovery rate was applied to correct for multiple testing
(α00.10). χ2 tests were used to evaluate proportions of change.
Pathway analyses were performed using Ingenuity Canon-
ical Pathway Analysis v.7.5 (Ingenuity Systems, Redwood
City, CA, USA), applying the complete Illumina Infinium
Array as the reference set. The unsupervised clustering meth-
od self-organising maps (SOM) was employed using Pear-
son's correlation (α00.01) with two endpoint classes (MeV
v.4.8). Data inclusion criteria for both Ingenuity's Pathway
Analysis and SOM analyses were: CpG sites significant after
correction for multiple testing with a methylation change
larger than the average methylation change of ±3.5 percentage
points. In the validation procedure, the selected CpG site from
the bead array was compared only with the same CpG site
analysed by Pyrosequencing or MassARRAY EpiTYPER.
Statistical testing was performed using a one-sided paired
t test, based on the a priori hypothesis of replicating findings
from the bead array. The dataset is available at the NCBI Gene
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Expression Omnibus (www.ncbi.nlm.nih.gov/geo, accessed
8 August 2012) under accession number GSE36166.
Results
DNA methylation profiling in human skeletal muscle We
employed Illumina's Infinium Bead Array to compare DNA
methylation of 27,578 CpG sites in close proximity to 14,475
gene transcription start sites in human skeletal muscle tissue
after control and HFO diets. The CpG sites were located up to
1,499 base pairs from transcription start, of which 53% were
located within 300 base pairs of transcription start and 73% in
CpG islands. We found that 66% of the CpG sites were
hypomethylated (methylated <25%), whereas 14% were
hypermethylated (methylated >75%) during the control diet
(n021) (electronic supplementary material [ESM] Fig. 1).
According to our a priori hypothesis, the randomised cross-
over design would minimise periodic, sequence and carry-
over effects, which is why we initially analysed all 21 partic-
ipants collectively. A total of 4,857 CpG sites (18%) distrib-
uted over 4,316 genes (30%) changed significantly after the
HFO diet, although this was non-significant when corrected
for multiple testing. However, by employing an unsupervised
cluster analysis with SOM including all 21 participants, we
detected an effect of the sequence in which participants re-
ceived the control vs HFO diet. SOM allocated the participants
into two groups based on similarities in their DNA methyla-
tion response following the dietary treatment, resulting in two
clusters with 11 and ten participants, respectively. Nine out of
the 11 participants grouped in the first cluster had received the
control diet first, followed by the HFO diet (Fig. 2). Eight out
of the ten participants who shifted from the initial HFO diet to
the control diet were grouped in the second cluster. Following
this observation, we analysed the participants according to the
sequence by which they had received each dietary treatment,
enabling us to document methylation changes induced by
HFO and the extent to which these were reversible (Fig. 1).
The group that received the control diet followed by HFO is
referred to as the ‘control diet first’ group (n011) and the
group that received the HFO diet followed by the control diet
is referred to as the ‘HFO first’ group (n010).
Clinical and metabolic changes All participants remained
weight stable and maintained their WHR between the
intervention periods (Table 1). In the control diet first
group, HFO led to significantly higher plasma glucose
levels and a higher hepatic IR index, whereas NEFA and
triacylglycerol levels decreased. Fasting insulin, total cho-
lesterol and M value remained unchanged. A shift from the
HFO diet back to the control diet in the HFO first group
led to an increase in fasting NEFA and total cholesterol
and a decrease in the hepatic IR index. No changes were
observed for fasting glucose, insulin, triacylglycerol and M
value (Table 1).
HFO induces DNA methylation changes (control diet first
group, n011) In the control diet first group and after correc-
tion for multiple testing, 7,909 CpG sites (29%) corresponding
to 6,508 genes (45%) changed significantly in response to
HFO. Thus, the proportion of genes with altered CpG methyl-
ation far exceeded the 724 genes (5%) that would be expected
to change by chance (χ2 p<0.0001). The average absolute
methylation change was 3.5±2.0 percentage points, with a
maximum methylation change of 13.0 percentage points
(Fig. 3 a, b). HFO led to an increase in DNA methylation in
83% of the affected CpG sites, among which 98% were
classified as hypomethylated (Fig. 3a). The top 20 most sig-
nificant genes included DNM2, MGMT, SLC2A3/GLUT3,
MRC1 and ACAT2 (all p<0.0001) (ESM Table 1). Further-
more, the top 20 genes showing the largest percentage points
increase or decrease in methylation following HFO included
APOH, DCC, ESRRG, FOLH1, GTF2I, MC4R and MYST4
(all methylation changes >10 percentage points) (ESM
Table 2). We selected 12 CpG sites/genes showing the quanti-
tatively largest significant methylation changes following the
HFO diet in the control diet first group for further validation
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Cluster 1 Cluster 2
Fig. 2 Unsupervised cluster analysis with SOMs. All 21 samples were
objectively divided into two clusters based on similarities in DNA
methylation changes following the HFO diet. Each vertical column
represents a participant and each horizontal line the methylation
change for one CpG site. The participants were each labelled with a
number and the order of dietary treatment. Individuals in the control
diet first group are labelled ‘Control→High-fat’ and individuals in the
HFO first group are labelled ‘High-fat→Control’. Increased methyla-
tion is indicated by green and decreased methylation by red
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with the two independent methods, Pyrosequencing and Mas-
sARRAY EpiTYPER, respectively. The validation analyses
confirmed a response in the same direction for all 12 CpG
sites/genes, with statistical significance for five and borderline
statistical significance for one of the genes (ESM Table 3).
Importantly, we also observed a good correlation between the
bead array expression data and each of the two validation
methods for nine out of the 12 CpG sites/genes, reaching
statistical significance for seven and borderline statistical sig-
nificance for two genes (ESM Table 3).
Pathways and candidate genes affected by HFO (control
diet first group, n011) Three consecutive pathway analyses
were performed to identify pathways with altered methylation
following HFO. The individual analysis included either hypo-
methylated, hypermethylated or both hypo- and hypermethy-
lated CpG sites collectively, which were objectively and
stringently selected as described in the statistics section. Sig-
nificant pathways for each group are presented in ESM
Table 4. When summarising significant pathways into
common diseases and disorders by Ingenuity for each analy-
sis, pathways relevant to common and potentially lifestyle-
related diseases including cancer (p00.005–0.05), the repro-
ductive system (p00.006–0.05) and inflammatory systems
(p00.0003–0.04) were predominantly represented (Table 2).
We used a candidate gene approach to search for associa-
tions between HFO and type 2 diabetes by focusing on 43 type
2 diabetes susceptibility genes. Significant changes were found
in 24 genes following HFO, for which methylation changes
were present in more than half of the CpG sites on the array for
AKT2, PDX1/IPF1, SLC30A8, CDKN2A, CDKN2B and
PPARG (ESM Table 5).
DNA methylation changes induced by HFO are slowly
reversed (HFO first group, n010) As noted previously, we
Table 1 Clinical and metabolic characteristics of study participants
Variable Control diet first group (n011) HFO first group (n010)
Control HFO HFO Control
Weight (kg) 78.5±8.3 77.5±7.0 76.7±11.3 76.5±10.1
BMI (kg/m2) 23.0±1.9 23.0±1.8 23.5±3.2 23.5±2.9
WHR 0.86±0.05 0.87±0.05 0.90±0.06 0.88±0.05
Fasting plasma glucose (mmol/l) 4.51±0.49 5.02±0.40* 5.08±0.45 4.71±0.48
Fasting serum insulin (pmol/l) 30.2±13.9 35.0±17.4 50.2±36.1 33.2±16.8
Fasting NEFA (μmol/l) 359±131 201±87* 201±69 335±137†
Fasting triacylglycerols (mmol/l) 0.86±0.29 0.62±0.20*** 0.74±0.45 0.88±0.39
Fasting total cholesterol (mmol/l) 3.90±0.76 3.89±0.63 4.10±0.75 4.37±0.60†††
M value ( μmol [kg FFM]−1min−1) 72.22±11.94 73.17±11.56 76.00±26.72 80.22±15.56
Hepatic IR index (μmol [kg FFM]−1min−1 [pmol/l]−1 371.1±218.9 577.8±360.0*** 700.0±321.1 395.0±153.3††
Data are means ± SD
Control diet first group: control vs HFO: * p<0.05, *** p<0.001
HFO diet first group: control vs HFO: † p<0.05, †† p<0.01, ††† p<0.001
FFM, fat-free mass
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Fig. 3 DNAmethylation changes induced by the HFO diet in the control
diet first group (n011). DNA methylation changes are given as percent-
age points (pp). (a) The number of CpG sites that showed an increase in
methylation following the HFO diet and the magnitude of the absolute
methylation changes. 0–1%: 154, 1–2%: 1,979, 2–3%: 1,811, 3–4%:
1,075, 4–5%: 679, 5–6%: 423, 6–7%: 235, 7–8%: 131, 8–9%: 46, 9–
10%: 12, 10–11%: 5, 11–12%: 2, 12–13%: 0, 13–14%: 1. (b) The number
of CpG sites that showed a decrease in methylation following the HFO
diet and the magnitude of the absolute methylation changes. 0–1%: 1, 1–
2%: 62, 2–3%: 120, 3–4%: 186, 4–5%: 214, 5–6%: 209, 6–7%: 201, 7–
8%: 152, 8–9%: 114, 9–10%: 55, 10–11%: 29, 11–12%: 11, 12–13%: 2
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observed an obvious difference in methylation response
based on the sequence by which the participants received
the control and HFO diets using SOM (Fig. 2). Only 341
genes (2%) changed in the HFO first group, which shifted
from initial HFO back to the control diet, of which none
were significant after correction for multiple testing (mean
change 2.9±1.7 percentage points, maximum change 13.1
percentage points). The proportion of genes that changed in
the control diet first group (45%) thus far exceeded the
changes seen in the HFO first group (2%) (χ2 p<0.0001).
Despite the limited changes observed in the HFO first
group, we were able to establish a general trend towards
reversibility of the DNA methylations, as indicated by the
reversed colour pattern between the control diet first and
HFO first group on the heatmap depicting the entire array
and by the SOM analysis (Fig. 2, ESM Fig. 2). To further
address the concept of reversibility, we examined the top
10% of genes (650 genes) that were most differentially
methylated after correction for multiple testing in the control
diet first group, to determine whether these showed signs of
reversibility in the HFO first group. We observed that 66%
of the genes that changed with the HFO diet had a methyl-
ation change in the opposite direction when switched back
to the control diet; however, this was significant for only
5%. This tendency was supported by an increase in mean
methylation of all 6,508 genes from 33.4% to 34.5% in the
control diet first group, and a decrease in mean methylation
from 34.1% to 33.7% in the HFO first group.
DNA methylation and gene expression To address the po-
tential transcriptional effects of the observed methylation
changes, we investigated the mRNA expression of methyl-
transferase enzymes and selected candidate genes of type 2
diabetes, as well as biologically relevant genes showing
large or significant DNA methylation changes following
HFO. Few gene expression changes were observed in either
the control diet first or HFO first groups (ESM Table 6). A
borderline increase was observed for DNMT3A (p00.08)
and DNMT1 (p00.10) during the HFO diet. The number
of CpG sites present on the array for each gene investigated
varied between one and 26, and correlations were performed
individually for each site (ESM Table 7). Significant corre-
lations between DNA methylation and gene expression were
observed for a minor proportion of the CpG sites and with
inconsistent direction.
Discussion
In this study, we extended our previous finding of increased
promoter methylation by short-term HFO of the metabolic
regulator PPARGC1A [16] to include almost half (45%) of
the CpG sites present on the bead array, documenting a
generalised regulatory epigenetic phenomenon introduced
by HFO. Although modest in absolute magnitude, the wide-
spread DNA methylation changes induced by HFO in this
study are quantitatively similar to those previously reported
to be influenced by HFO in selected candidate genes impli-
cated in growth and metabolic disease, including type 2
diabetes [14, 16, 18, 22, 23]. However, the extent to which
general epigenetic changes play a role in the short-term
regulation of metabolic functions in muscle by HFO, includ-
ing IR, remains to be established.
The functional read-out of altered DNA methylation has
traditionally been thought to involve altered mRNA expres-
sion, and significant correlations between DNA promoter
methylation and distinct gene expression has previously
been reported in some [13, 15] but not all human studies,
including the Human Epigenome Project, supporting the
notion that the relationship between DNA methylation and
gene expression is not always straightforward [14, 16, 24].
Few significant correlations were observed between DNA
Table 2 Ingenuity Canonical Pathway Analysis, showing common diseases and disorders with the largest significant methylation differences
following the HFO diet in the control diet first group (n011)
Pathway analysis CpG sites/genes in analysis Molecules Common diseases/disorders p value
Hypomethylated CpG sites 1,989/1,853 375 Cancer 0.005–0.05
151 Reproductive system disease 0.006–0.05
115 Gastrointestinal disease 0.02–0.04
Hypermethylated CpG sites 862/812 60 Inflammatory disease 0.0003–0.04
95 Inflammatory response 0.0004–0.04
35 Ophthalmic disease 0.0004–0.03
Both hypo- and hypermethylated CpG sites 3,162/2,914 99 Cancer 0.007–0.05
83 Reproductive system disease 0.02–0.05
4 Infection mechanism 0.02
The top three common diseases and disorders are presented according to hypomethylated, hypermethylated and both hypo- and hypermethylated
CpG sites/genes
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methylation and gene expression levels for a number of
candidate genes in the present study. Although this may
question the immediate functional relevance of the wide-
spread methylation changes, it remains possible that the
methylation changes may influence the expression levels
of some genes if HFO is maintained over longer periods of
time, as indicated by the slow reversibility of the HFO-
induced methylation changes. The methylation changes
may also only influence gene expression during specific
metabolic challenges or demands, such as in response to
acute exercise [25, 26], or perhaps in subgroups predisposed
to metabolic disease, such as individuals born with low
birthweight [16]. To this end, the possibility that the meth-
ylation changes induced by HFO actually prevented poten-
tially detrimental effects of HFO on gene expression,
representing a homeostatic mechanism, should be men-
tioned. It has even been suggested that changes in methyl-
ation could actually represent a consequence—and not a
cause—of altered transcriptional activity [27]. In addition,
the bead array screens a minor portion of the CpG sites in
the genome, and we cannot exclude that other regions, such
as enhancer regions, are regulatory important for gene ex-
pression [28]. All together, the extent to which the observed
changes in DNA methylation in this study affect gene ex-
pression over time, in a subset of individuals at risk or
during certain specific metabolic challenges remain to be
determined.
The induction of DNA methylation changes after 5 days
of HFO supports the growing awareness of DNA methyla-
tion as a dynamic signal that is possibly relevant to short-
term day-to-day metabolic adaptations, including acute ex-
ercise [26, 29, 30]. However, our finding of a slow revers-
ibility rate indicates the demethylation process may be
somewhat impeded compared with the induction of methyl-
ation changes by diet, which could have implications for the
preservation or build-up of CpG methylation over time.
Diverging DNA methylation levels between elderly, but
not young, genetically identical twins indicate that environ-
mental exposures throughout life may permanently influ-
ence DNA methylation, suggesting some preservation of de
novo DNA methylation in adults [9]. A slow reversibility of
DNA methylation induced by carcinogenic agents has like-
wise been observed due to ingestion of high-fat diets in
rodents [19, 20]. As skeletal muscle is a terminally differ-
entiated tissue, methylations induced by HFO could be
introduced by de novo or maintenance DNA methylation
enzymes, including DNMT3A, DNMT3B and DNMT1 [31,
32]. We observed no significant methylation changes in
these genes. However, we did observe borderline significant
increased expression levels of DNMT3A and of DNMT1
during HFO, similar to observations in transgenic mice
following a high-fat diet [33]. More data are needed to
determine the role of specific DNA methyltransferases in
the regulation of DNA methylation induced by high-fat
diets.
Applying Ingenuity's pathway analyses, we found in-
creased methylation of CpG sites associated with genes
involved in the reproductive system and cancer; conversely,
we found decreased methylation of genes encoding inflam-
matory pathways. It is well known that obesity is associated
with decreased fertility and certain types of cancers [34, 35].
Likewise, a high level of NEFAs is associated with IR and
low-grade inflammation and may potentially be involved in
the development of type 2 diabetes [36–38]. The decreased
plasma NEFA levels following the HFO diet indicate de-
creased lipolyses, but could also reflect increased NEFA
uptake and storage in the muscle [38, 39]. We did not find
any disproportionately large or distinct methylation changes
in 43 selected type 2 diabetes genes, emphasising the gen-
eral nature of the response. Future studies are required to
elucidate the role of altered methylation in specific genes or
pathways and its potential impact on disease development.
As in all biological research, positive findings may have
occurred by chance or random variation of data. However,
we do not believe that this is the case with the methylation
changes induced by HFO in the present study. First and
most importantly, the SOM analysis classified the samples
into two groups based on the order of the dietary treatments
with great accuracy, providing strong intrinsic validity of the
array results. In other words, the SOM analysis showed
relatively smaller variation between arrays per se, as op-
posed to the effects of the HFO intervention. Second, the
control and HFO samples were evenly distributed on differ-
ent arrays and run on the same day, which eliminates the
consideration that variation from one or two arrays could be
responsible for the HFO response. Third, validation studies
using two independent DNA methylation assessment meth-
ods supported the findings from the bead array analyses
showing DNA methylations changing in the same direction
for all 12 out of 12 CpG sites/genes tested and with good
concordance between the methods. Given a variation in
methylation of 5% between repeated measurements for both
validation methods and the relatively small methylation
differences detected with the bead arrays in response to
HFO, we do not find it surprising or against our array
findings that not all methylation changes were of the exact
same magnitude, and that some failed to show statistical
significance in the validation analyses. In addition, the lack
of statistical significance for some DNA methylation
changes in the validation process is likely to be due to the
fact that limited muscle biopsy material was available, re-
ducing the sample size to eight for some genes, which of
course also reduced the statistical power compared with the
array analyses. Finally, we did observe that the Pyrose-
quencing technique tended to be less sensitive in detecting
low degrees of DNA methylations, and since SNX7 and
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STC1 showed the lowest degrees of methylation, we ascribe
the limited DNA methylation changes to insensitivities of
the Pyrosequencing method at low methylation levels.
Regardless, the data of course need to be replicated in other
studies.
In summary, we report for the first time that short-term
HFO introduces DNA methylation changes on a genome-
wide scale in human skeletal muscle. These changes were
only partly reversed after 6–8 weeks. These broad changes,
while modest in magnitude, highlight the plasticity and re-
versibility of DNA methylation levels in response to dietary
interventions in humans. The relevance of these findings in
causing or buffering human disease, including type 2 diabetes,
remains to be determined.
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